Apogee Therapeutics (APGE) Cash & Equivalents (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Cash & Equivalents data on file, last reported at $451.8 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $451.8 million, up 322.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $451.8 million (up 322.57% YoY), and the FY2025 annual result was $131.5 million, down 7.22% from the prior year.
• Cash & Equivalents grew to $451.8 million in Q1 2026 per APGE's latest filing, from $131.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $485.5 million in Q1 2024 and troughed at $5.0 million in Q2 2022.
• A 5-year average of $183.2 million and a median of $128.3 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents surged 2415.08% in 2023, then slumped 77.98% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $151.9 million in 2022, then dropped by 22.1% to $118.3 million in 2023, then gained by 19.84% to $141.8 million in 2024, then retreated by 7.22% to $131.5 million in 2025, then soared by 243.44% to $451.8 million in 2026.
• Business Quant data shows APGE's Cash & Equivalents at $451.8 million in Q1 2026, $131.5 million in Q4 2025, and $107.9 million in Q3 2025.